Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers

OTTMAR LEISS AND KLAUS VON BERGMANN

From the Department of Medicine, University of Bonn, Bonn, Federal Republic of Germany

SUMMARY The effect of Rowachol (200 mg tid), an essential oil preparation, on biliary lipid secretion and serum lipids was measured in six healthy male volunteers before and after four weeks of treatment. Biliary cholesterol and phospholipid secretion increased significantly from 113 ± 36 (SD) $\mu\text{mol/h}$ to 155 ± 52 $\mu\text{mol/h}$ ($p < 0.05$) and from 409 ± 145 $\mu\text{mol/h}$ to 587 ± 185 $\mu\text{mol/h}$ ($p < 0.05$), respectively. Bile acid secretion increased from 1519 ± 662 $\mu\text{mol/h}$ to 2287 ± 1175 $\mu\text{mol/h}$ ($p > 0.05$ and > 0.10). This marked increase in biliary lipid secretion was not followed by a change in molar composition of biliary lipids and lithogenicity of bile. Serum cholesterol and triglycerides declined from 4.9 mmol/l to 4.1 mmol/l ($p < 0.05$) and from 1.2 mmol/l to 0.9 mmol/l ($p < 0.05$) respectively. The ratio of high-density-lipoprotein cholesterol to total cholesterol increased from 0.22 to 0.31 ($p < 0.05$). Although it has been shown previously that Rowachol could dissolve cholesterol gall stones the present results indicate that Rowachol alone has only weak litholytic properties, at least in normal volunteers, but might have several advantages when combined with chenodeoxycholic or ursodeoxycholic acid.

Chronic administration of either chenodeoxycholic acid or ursodeoxycholic acid has been shown to reduce lithogenicity of bile thereby promoting dissolution of cholesterol gall stones.¹⁻³ Recently, another agent, Rowachol, has been shown to be effective in dissolving gall stones^{4,5} and biliary tract stones.⁶ This essential oil preparation containing the mono- and bicyclic monoterpenes menthol (32% w/v), pinene (17% w/v), menthone (6% w/v), borneol (5% w/v), camphene (5% w/v) and cineole (2% w/v) in olive oil (ROWA-Wagner KG, 5060 Bergisch-Gladbach 1, FRG) has been used as a choleric and therapeutic agent for biliary tract diseases in Europe for more than 25 years.^{7,8} Whereas chenodeoxycholic acid and ursodeoxycholic acid reduce the lithogenicity of bile by decreasing biliary lipid output of cholesterol⁹⁻¹¹ the mechanism by which Rowachol effect biliary lipid metabolism has not been elucidated. The purpose of the present study was to examine the effects of Rowachol on biliary lipid secretion and serum lipid concentration in normal volunteers.

Address for correspondence: Ottmar Leiss, MD, Medizinische Klinik, Universitaet Bonn, Sigmund-Freud-Strasse 25, 5300 Bonn-Venusberg, Federal Republic of Germany.

Received for publication 16 March 1984

Methods

EXPERIMENTAL DESIGN

Six healthy young male volunteers were studied as outpatients at the Metabolic Unit, Department of Medicine, University of Bonn. The study was conducted in accordance with the principles of the Helsinki declaration and informed consent was obtained from each subject. None of the subjects had evidence of gastrointestinal disease and routine liver function tests were normal. Age, body weight, and height are given in Table 1. During the study period each subject was on his usual diet and no changes in body weight occurred.

Biliary lipid secretion rates were measured before

Table 1 Age, body weight and height of the volunteers

Subject	Age (yr)	Body weight (kg)	Height (cm)
1	23	84	184
2	22	76	192
3	25	77	190
4	26	74	187
5	25	70	176
6	26	69	180

and after four weeks of administration of Rowachol (200 mg tid). Blood was taken after an overnight fast before and after two and four weeks of administration of Rowachol. Serum was separated and stored at -20°C until serum lipid analysis.

EXPERIMENTAL PROCEDURE

Biliary lipid secretion was measured by the intestinal perfusion technique described by Grundy and Metzger.¹² The evening before the study the subjects were admitted to the Metabolic Ward where they swallowed a triple lumen tube. After an overnight fast the tube was positioned with two proximal outlets adjacent to the ampulla of Vater and a third outlet 10 cm distally just beyond the ligamentum of Treitz. A liquid formula diet (142 cal/kg/h) containing 36% of calories as fat (70% in the form of lard), 16% as protein and 48% as carbohydrates (Nutrodrip, Wander GmbH, 6522 Osthofen, FRG) together with beta-sitosterol (22.5 mg/h) as a non-absorbable marker were infused constantly through the most proximal outlet. After allowing four hours for gall bladder contraction and stabilisation of hepatic bile secretion hourly samples were obtained for the following six hours from the second proximal and the distal outlet by continuous aspiration. During the regimen of Rowachol administration 400 mg of this terpene mixture was given in the morning of the study before liquid formula infusion was started.

Storage of the proximal samples and separation of bile acids from cholesterol and phospholipids were performed according to the method used in the National Cooperative Gallstone Study.¹³ Ten millilitres of the distal samples were added to ethanol. In every proximal and distal sample, cholesterol and beta-sitosterol were measured by gas liquid chromatography as trimethylsilyl ethers¹⁴ using 5- α -cholestane as internal standard. In every proximal sample bile acids were determined enzymatically^{15,16} and phospholipids were measured by the method of Bartlett.¹⁷ Hourly outputs of cholesterol, bile acids and phospholipids were then calculated according to equations given by Grundy and Metzger¹² along with correction factors for cholesterol content of the perfused formula. Biliary lipid composition was expressed as molar per cent for each lipid component according to Admirand and Small¹⁸ and per cent saturation was calculated by the criteria of Carey and Small¹⁹ assuming a total lipid content of hepatic bile of 5 g/dl.

Individual bile acids were determined in every proximal sample by gas liquid chromatography. The conjugated bile acids were deconjugated enzymatically (cholyglycin hydrolase; Sigma Chemicals Co, St. Louis, Mo. (20)) and solvolised.²¹

After methylation²² and derivatisation to their trimethylsilyl ethers¹⁴ the individual bile acids were separated on a fused silica capillary column (SP 2100, 25 m, ID 0.20–0.21 mm, Hewlett Packard, Palo Alto, CA) using an automatic injection system (7671 A Automatic Sampler, Hewlett Packard).

SERUM LIPIDS

Total lipids, cholesterol, phospholipids and triglycerides were determined by the micromethod of Egge *et al.*²³ High-density-lipoprotein cholesterol was determined in the supernatant after precipitation of apolipoprotein-B containing lipoproteins with dextran sulphate/magnesium chloride²⁴ using a micromethod described recently.²⁵ Previous studies by one of us²⁵ have shown that high-density-lipoprotein-cholesterol determined by this micromethod was in good agreement with high-density-lipoprotein-cholesterol determined by ultracentrifugation according to Havel *et al.*²⁶

STATISTICAL ANALYSIS

The results are expressed as mean $\pm$ SD. Results between control period and Rowachol administration were compared with the Wilcoxon's signed rank test.

Results

EFFECT OF ROWACHOL ON BILIARY LIPID SECRETION

Biliary lipid outputs during control period and after administration of Rowachol are given in Table 2. Biliary cholesterol secretion averaged 113 $\mu\text{mol/h}$ during control period and increased after administration of Rowachol by 37% to 155 $\mu\text{mol/h}$ ($p < 0.05$). Biliary secretion of phospholipids averaged 409 $\mu\text{mol/h}$ during control period and increased significantly by 36% to 587 $\mu\text{mol/h}$ during Rowachol treatment ($p < 0.05$). The average increase in bile acid secretion from 1519 $\mu\text{mol/h}$ to 2287 $\mu\text{mol/h}$ (51%) was not significant ($p > 0.05$ and < 0.10). Administration of Rowachol had no effect on molar composition of cholesterol, bile acids, phospholipids or the lithogenic index (Table 3). Molar ratios of cholesterol to bile acids, cholesterol to phospholipids and phospholipids to bile acids during the control period averaged 0.09 ± 0.03 , 0.29 ± 0.09 and 0.28 ± 0.07 , respectively. Administration of Rowachol did not alter these ratios (0.08 ± 0.03 , 0.27 ± 0.05 and 0.29 ± 0.09 , respectively). No change in the molar composition of individual bile acids was observed during administration of Rowachol, except for lithocholic acid, the smallest fraction, which increased (Table 4).

Table 2 Biliary lipid secretion rates in normal volunteers during control period and after four weeks of treatment with Rowachol (200 mg tid)

Subject	Cholesterol ($\mu\text{mol/h} \pm \text{SD}$)		Phospholipids ($\mu\text{mol/h} \pm \text{SD}$)		Bile acids ($\mu\text{mol/h} \pm \text{SD}$)	
	CO	ROW	CO	ROW	CO	ROW
1	151 $\pm$ 16	133 $\pm$ 43	579 $\pm$ 92	582 $\pm$ 269	1484 $\pm$ 252	1845 $\pm$ 894
2	90 $\pm$ 14	141 $\pm$ 22	253 $\pm$ 65	673 $\pm$ 173	913 $\pm$ 177	2752 $\pm$ 548
3	122 $\pm$ 17	155 $\pm$ 18	590 $\pm$ 146	568 $\pm$ 117	2689 $\pm$ 755	2570 $\pm$ 720
4	57 $\pm$ 8	119 $\pm$ 43	334 $\pm$ 149	473 $\pm$ 166	1415 $\pm$ 240	1090 $\pm$ 354
5	151 $\pm$ 5	255 $\pm$ 41	405 $\pm$ 34	884 $\pm$ 191	1725 $\pm$ 179	4245 $\pm$ 596
6	109 $\pm$ 23	125 $\pm$ 22	295 $\pm$ 59	339 $\pm$ 65	888 $\pm$ 214	1219 $\pm$ 265
$\bar{x} \pm \text{SD}$	113 $\pm$ 36	155 $\pm$ 51†	409 $\pm$ 145	587 $\pm$ 185†	1519 $\pm$ 662	2287 $\pm$ 1175‡

Abbreviations: CO = Control period; ROW = Rowachol period.

* Values for each subject represent the average for 6 determinations during the steady state period of formula infusion.

† Significantly different from CO ($p < 0.05$).

‡ p between 0.05 and 0.10.

EFFECT OF ROWACHOL ON SERUM LIPIDS

Mean total lipids, cholesterol, triglycerides and phospholipids before, after two and four weeks of treatment with Rowachol are presented in Table 5. A significant reduction of triglyceride concentration in serum was observed after two and four weeks. Phospholipids and total lipids showed a significant decrease after four weeks. High-density-lipoprotein-cholesterol increased slightly (14%) after four weeks, and with the parallel small but not significant decrease in total cholesterol the ratio of high-density-lipoprotein-cholesterol to total cholesterol increased significantly ($p < 0.05$).

Discussion

EFFECTS OF ROWACHOL ON BILIARY LIPID SECRETION

The results of this study in normal volunteers show that administration of Rowachol (200 mg tid) for

four weeks increases biliary outputs of bile acids, phospholipids, and cholesterol to almost the same rate extending previous studies in animals²⁷ and preliminary results in patients with indwelling T-tube after cholecystectomy.²⁸ The obtained secretion rates of biliary lipids are in the same range as in other groups of normal volunteers published previously²⁹ as well as studied recently in our department. (In 20 healthy volunteers the hourly secretion rates of cholesterol, phospholipids, bile acids and the LI of hepatic bile averaged 120 ± 19 , 420 ± 140 , 1776 ± 277 $\mu\text{mol/h}$ and 0.96 ± 0.26 , respectively). Whether the present results obtained in normal volunteers might be extrapolated to patients with cholesterol gall stones has to be elucidated. How Rowachol promote this parallel increase in output of all biliary lipids remains unclear. Other drugs for treatment of cholesterol gall stone disease or hyperlipidemia do not induce such remarkable effects on biliary lipid secretion.

Table 3 Biliary lipid composition and lithogenic index of stimulated hepatic bile in normal volunteers during control period and after 4 weeks of treatment with Rowachol (200 mg tid)

Subject	Cholesterol (molar %) (mean $\pm$ SD*)		Phospholipids (molar %) (mean $\pm$ SD*)		Bile acids (molar %) (mean $\pm$ SD*)		Lithogenic Index (CS) (mean $\pm$ SD*)	
	CO	ROW	CO	ROW	CO	ROW	CO	ROW
1	6.9 $\pm$ 0.7	5.6 $\pm$ 1.3	26.2 $\pm$ 1.5	24.0 $\pm$ 6.5	66.9 $\pm$ 2.0	70.4 $\pm$ 6.8	0.93 $\pm$ 0.11	0.84 $\pm$ 0.19
2	7.2 $\pm$ 0.7	4.0 $\pm$ 0.3	20.3 $\pm$ 5.2	18.7 $\pm$ 2.1	72.5 $\pm$ 5.6	77.3 $\pm$ 2.1	1.18 $\pm$ 0.08	0.71 $\pm$ 0.05
3	3.7 $\pm$ 0.6	4.9 $\pm$ 0.8	17.5 $\pm$ 1.7	17.4 $\pm$ 1.1	78.8 $\pm$ 2.0	77.7 $\pm$ 1.9	0.70 $\pm$ 0.11	0.91 $\pm$ 0.14
4	3.2 $\pm$ 0.2	7.1 $\pm$ 1.3	18.1 $\pm$ 5.1	28.2 $\pm$ 4.7	78.7 $\pm$ 5.2	64.7 $\pm$ 5.9	0.59 $\pm$ 0.12	0.93 $\pm$ 0.20
5	6.6 $\pm$ 0.4	4.7 $\pm$ 0.5	17.8 $\pm$ 0.5	16.3 $\pm$ 1.8	75.6 $\pm$ 0.8	79.0 $\pm$ 1.9	1.20 $\pm$ 0.07	0.92 $\pm$ 0.07
6	8.5 $\pm$ 0.1	7.5 $\pm$ 0.7	23.0 $\pm$ 2.3	20.3 $\pm$ 1.4	68.5 $\pm$ 2.8	72.2 $\pm$ 2.0	1.29 $\pm$ 0.09	1.23 $\pm$ 0.10
$\bar{x} \pm \text{SD}$	6.0 $\pm$ 2.1	5.6 $\pm$ 1.4	20.5 $\pm$ 3.5	20.8 $\pm$ 4.5	73.5 $\pm$ 5.1	73.6 $\pm$ 5.5	0.98 $\pm$ 0.29	0.92 $\pm$ 0.17

Abbreviations: CO = Control period; ROW = Rowachol period; CS = Lithogenic Index calculated according to Carey and Small¹⁹ assuming a total lipid content of hepatic bile of 5 g/dl.

* Values for each subject represent the average for 6 determinations during the steady state period of formula infusion.

Table 4 Mean molar per cent of individual bile acids in bile in normal volunteers during control period and after four weeks of treatment with Rowachol (200 mg tid)

Subject	LICA (molar %*)		DCA (molar %*)		CDCA (molar %*)		CA (molar %*)		UDCA (molar %*)	
	CO	ROW	CO	ROW	CO	ROW	CO	ROW	CO	ROW
1	0.29	1.09	19.95	31.58	39.24	38.82	37.64	29.48	2.87	1.04
2	0.52	0.72	24.03	24.16	41.15	47.33	30.03	24.07	4.26	3.72
3	0.12	0.98	20.80	19.45	43.37	43.48	30.64	32.03	5.08	4.06
4	0.98	1.03	25.79	23.01	53.12	46.58	15.32	26.14	4.80	3.24
5	0.85	1.86	15.20	19.42	43.92	44.55	39.07	33.15	0.96	1.02
6	1.26	1.17	17.32	12.29	49.62	49.33	30.11	36.10	1.69	1.11
Mean	0.67	1.14†	20.51	21.65	45.07	45.02	30.16	30.47	3.28	2.37
±SD	0.43	0.38	3.98	6.39	5.27	3.67	4.50	8.43	1.71	1.46

Abbreviations: LICA = lithocholic acid; DCA = deoxycholic acid; CDCA = chenodeoxycholic acid; CA = cholic acid; UDCA = ursodeoxycholic acid; CO = Control period; ROW = Rowachol period.

* Values for each subject represent the average for 6 determinations during the steady state period of formula infusion.

† Significantly different from CO ($p < 0.05$).

The observed increase of biliary lipid output had no consistent effect on lithogenicity of hepatic bile. Molar ratios of cholesterol to bile acids, cholesterol to phospholipids and phospholipids to bile acids were not changed after Rowachol administration indicating that this terpene mixture did not alter the coupling of cholesterol or phospholipids to bile acids. As shown in Table 3, however, in four of the volunteers with a lithogenic index greater than 0.9 treatment with Rowachol slightly decreased the lithogenic index. These results are comparable with those of acute studies by Doran *et al.*³⁰ With the same dose regimen these investigators found a significant decrease in cholesterol saturation of gall bladder bile obtained by needle aspiration in patients at the time of abdominal surgery.

EFFECTS OF ROWACHOL ADMINISTRATION ON SERUM LIPIDS

The beneficial effects of Rowachol on serum lipids

Table 5 Mean serum lipids during control period and after 2 weeks and 4 weeks of administration of Rowachol (200 mg tid)

	CO (mean±SD)	2 weeks (mean±SD)	4 weeks (mean±SD)
Total lipids (g/l)	6.53±0.91	6.40±0.69	5.22±1.14*
Triglycerides (mmol/l)	1.22±0.29	0.95±0.22*	0.87±0.29*
Phospholipids (mmol/l)	2.89±0.92	3.09±0.68	2.09±0.62*
Total cholesterol (mmol/l)	4.91±0.38	4.89±0.63	4.07±0.64
HDL-cholesterol (mmol/l)	1.09±0.14	1.38±0.32	1.25±0.23
HDL-cholesterol	0.22±0.04	0.28±0.06*	0.31±0.05*
Total cholesterol			

Abbreviations: CO = Control period; ROW = Rowachol period.

* Significantly different from CO ($p < 0.05$).

support previous studies in patients with cholestasis²⁸ and hyperlipoproteinaemia.³¹⁻³³ The significant increase in the absolute values of high-density-lipoprotein-cholesterol during treatment with this terpene preparation observed by Bell *et al.*³⁴ and Hordinsky and Hordinsky³³ could not be confirmed in the present study, probably because normolipidemic volunteers were studied during shorter treatment periods. When expressed as relative values, however, (ratio of high-density-lipoprotein-cholesterol to total cholesterol) the change from 0.22 to 0.31 was statistically significant ($p < 0.05$). The beneficial effect of this terpene preparation on serum lipids might be of advantage for treatment of hyperlipidemic patients with increased risk factors for gall stone formation as common lipid lowering drugs like clofibrate,^{35 36} bezafibrate,³⁷ and probably nicotinic acid^{36 38} increase lithogenicity of bile.

MECHANISM OF CHOLESTEROL GALL STONE DISSOLUTION BY ROWACHOL

The mechanism whereby Rowachol induces cholesterol gall stone dissolution is not clear. In the present study the lithogenic index in normal volunteers was not influenced consistently by Rowachol, in contrast with known effects of chenodeoxycholic acid and ursodeoxycholic acid. Thus, other effects after Rowachol administration seems also to be important for gall stone dissolution. In addition to the relative concentration of bile acids, phospholipids and cholesterol total lipid content of bile is another important determinant of cholesterol solubility.¹⁹ In the present study Rowachol increased total lipid output and total lipid concentration of duodenal content (0.67 g/l versus 0.87 g/l; $p < 0.05$). This observation is in line with results of

Bell *et al.*³⁹ who show that Rowachol (100 mg tid) given to gall stone patients three months before cholecystectomy increased biliary lipid concentration significantly. Thus, the increase in biliary lipid concentration produced by Rowachol might contribute to the litholytic properties of this mixture of plant monoterpenes. Furthermore, several of the terpenes – for example, menthol, menthone and pinene – are excellent cholesterol solvents *in vitro*. The structurally related terpene, d-limonene, has recently been used as an agent for dissolving common duct stones.⁴⁰ Therefore, physico-chemical properties of some of the individual components of Rowachol may also contribute to the cholelitholytic effects. Although, administration of Rowachol alone might dissolve gall stone in some patients,^{4 5 41} a combination with chenodeoxycholic acid or ursodeoxycholic acid might be of advantage for several reasons. First, the dissolution rates of gall stone may be accelerated, as already shown by Ellis *et al.*^{41 42} Second, the dose of chenodeoxycholic acid or ursodeoxycholic acid might be lowered, decreasing the cost of medical gall stone dissolution. And third, the lipid lowering effect of this essential oil preparation may prevent the increase of LDL-cholesterol observed by the National Cooperative Gallstone Study during chenodeoxycholic acid therapy.⁴³ A combination of Rowachol with ursodeoxycholic acid might be even more effective in reducing lithogenicity of bile. Preliminary results from our department in a randomised study indicate that low dose ursodeoxycholic acid (250 mg/day) combined with Rowachol decreased the lithogenic index of super-saturated gall bladder bile in patients with gall stones and/or hyperlipoproteinaemia more (from 1.88 to 1.02; $p < 0.01$, $n=6$) than low dose chenodeoxycholic acid (250 mg/day) plus Rowachol (from 1.32 to 1.33; $n=6$) or ursodeoxycholic acid alone (1000 mg/day; from 1.00 to 0.77; $p < 0.05$, hepatic bile, $n=6$).

The work was supported by grant Le 385/1 of the Deutsche Forschungsgemeinschaft, Bonn, FRG. The authors thank Mrs P Pitters and G Westphal and Mr S Weiner for excellent technical assistance.

References

- 1 Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. *N Engl J Med* 1972; **286**: 1–8.
- 2 Bell CD, Whitney B, Dowling RH. Gallstone dissolution in man using chenodeoxycholic acid. *Lancet* 1972; **2**: 1213–6.
- 3 Makino J, Shinizaki K, Nakagawa K, Yoshino K. Dissolution of cholesterol gallstones by ursodeoxycholic acid. *Jpn J Gastroenterol* 1975; **72**: 690–702.
- 4 Hordinsky BZ. Terpenes in the treatment of gallstones. *Minn Med* 1971; **54**: 649–52.
- 5 Bell GD, Doran J. Gall stone dissolution in man using an essential oil preparation. *Br Med J* 1979; **279**: 24.
- 6 Ellis WR, Bell GD. Treatment of biliary duct stones with a terpene preparation. *Br Med J* 1981; **282**: 611.
- 7 Sarreither W. Rowachol-Cholex, ein terpenhaltiges Praeparat zur Behandlung der Cholelithiasis. *Med Monatsschr* 1955; **9**: 97–9.
- 8 Weithaler K. Zur Therapie der Gallenwegserkrankungen. *Med Klinik* 1959; **54**: 1645–9.
- 9 Adler RD, Bennion LJ, Duane WC, Grundy SM. Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism. *Gastroenterology* 1975; **68**: 326–34.
- 10 LaRusso NF, Hoffman NE, Hofmann AF, Northfield TC, Thistle JL. Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients. *Gastroenterology* 1975; **69**: 1301–14.
- 11 Von Bergmann K, Epple-Gutsfeld M, Leiss O. Differences in the effects of chenodeoxycholic and ursodeoxycholic acid on biliary lipid secretion and bile acid synthesis in patients with gallstones. *Gastroenterology* 1984; **87**: 136–43.
- 12 Grundy SM, Metzger AL. A physiological method for estimation of hepatic secretion of biliary lipids in man. *Gastroenterology* 1972; **62**: 1200–17.
- 13 Hofmann AF, Grundy SM, Lachin JM, *et al.* Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the National Cooperative Gallstone Study. *Gastroenterology* 1982; **83**: 738–52.
- 14 Grundy SM, Ahrens EH Jr, Miettinen TA. Quantitative isolation and gas-liquid chromatographic analysis of total fecal bile acids. *J Lipid Res* 1965; **6**: 397–410.
- 15 Talalay P. Enzymatic analysis of steroid hormones. *Methods Biochem Anal* 1960; **8**: 114–43.
- 16 Paumgartner G, Horak W, Probst P, Grabner G. Effect of phenobarbital on bile flow and bile salt excretion in the rat. *Naunyn-Schmiedeberg's Arch Pharmacol* 1971; **270**: 98–102.
- 17 Bartlett GR. Phosphorous assay in column chromatography. *J Biol Chem* 1959; **234**: 466–8.
- 18 Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man. *J Clin Invest* 1968; **47**: 1043–52.
- 19 Carey M, Small DM. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. *J Clin Invest* 1978; **61**: 998–1026.
- 20 Nair PP, Gordon M, Reback J. The enzymatic cleavage of the carbon-nitrogen bond in 3- α ,7- α ,12- α -trihydroxy-5- β -cholan-25-oxyglycine. *J Biol Chem* 1967; **242**: 7–11.
- 21 van Berge Henegouwen GP, Allan RN, Hofmann AF, Yu PYS. A facile hydrolysis-solvolysis procedure for conjugated bile acid sulfates. *J Lipid Res* 1977; **18**: 118–22.
- 22 Schlenk H, Gellermann JL. Esterification of fatty acids with diazomethane on a small scale. *Anal Chem* 1960; **32**: 1412–4.

- 23 Egge H, Murawski U, Mueller J, Zilliken F. Mikrolipidanalysen aus Serum mit dem Eppendorfsystem 3000. *Z Klin Chem Klin Biochem* 1970; **8**: 488–91.
- 24 Burstein M, Scholnick HR. Lipoprotein-polyanion-metal interactions. *Adv Lipid Res* 1973; **11**: 67–108.
- 25 Leiss O, Murawski U, Egge H. Mikrobestimmung von Lipoproteinlipiden im Serum. *J Clin Chem Clin Biochem* 1979; **17**: 619–25.
- 26 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. *J Clin Invest* 1955; **34**: 1345–53.
- 27 Moersdorf K, Wolf G. Untersuchungen zur Wirkungspotenz einiger Choleretika. *Dtsch Med J* 1966; **10**: 303–6.
- 28 Kopp H. Zur klinischen Wirksamkeit von Rowachol. *Arch Arzneit* 1976; **1**: 21–38.
- 29 von Bergmann K, Mok HY, Hardison WGM, Grundy SM. Cholesterol and bile acid metabolism in moderately advanced, stable cirrhosis of the liver. *Gastroenterology* 1979; **77**: 1183–92.
- 30 Doran J, Keighley MRB, Bell GD. Rowachol – a possible treatment for cholesterol gallstones. *Gut* 1979; **20**: 312–7.
- 31 Clotten R. Wirksamkeit des Terpengemisches Rowachol bei gestoerter Leberfunktion. *Muench Med Wochenschr* 1972; **114**: 256–61.
- 32 Beiglboeck W. Ueber die Wirkung aetherischer Oele auf die sekretorische Leberfunktion und das Serumcholesterin. *Wiener Med Wochenschr* 1960; **110**: 11–6.
- 33 Hordinsky BZ, Hordinsky W. Rowachol – seine Verwendung bei Hyperlipaemie. *Arch Arzneit* 1979; **1**: 45–51.
- 34 Bell GD, Bradshaw JP, Burgess A, et al. Elevation of serum high density lipoprotein cholesterol by Rowachol, a proprietary mixture of six pure monoterpenes. *Atherosclerosis* 1980; **36**: 47–54.
- 35 Pertsemlidis D, Panveliwalla D, Ahrens EH Jr. Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. *Gastroenterology* 1977; **66**: 565–73.
- 36 Angelin B, Einarsson K, Leijdt B. Biliary lipid composition during treatment with different hypolipidaemic drugs. *Eur J Clin Invest* 1979; **9**: 185–90.
- 37 von Bergmann K, Leiss O. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia. *Eur J Clin Invest* 1984; **14**: 150–4.
- 38 Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. *J Lipid Res* 1981; **22**: 24–36.
- 39 Bell GD, Clegg RJ, Ellis WR, Middleton B, Sommerville K, White DA. How does Rowachol, a mixture of plant monoterpenes, enhance the litholytic potential of low and medium dose chenodeoxycholic acid? *Br J Clin Pharmacol* 1982; **13**: 278P–9P.
- 40 Igimi H, Hisatsugu T, Nishimura M. The use of d-limonen preparation as a dissolving agent of gallstones. *Dig Dis* 1976; **21**: 926–39.
- 41 Ellis WR, Somerville KW, Rose DH, Axon ATR, Bell GD. Terpene treatment for gallstones: five year experience with Rowachol 1977–82. [Abstract] *Gut* 1982; **23**: A882–3.
- 42 Ellis WR, Bell GD, Middleton B, White DA. Adjunct to bile-acid treatment for gall-stone dissolution: low-dose chenodeoxycholic acid combined with a terpene preparation. *Br Med J* 1981; **282**: 611–2.
- 43 Albers JJ, Grundy SM, Cleary PA, Small DM, Lachin JM, Schoenfeld LJ, and the National Cooperative Gallstone Study Group: National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. *Gastroenterology* 1982; **82**: 638–46.